Welcome to our dedicated page for Synopsys SEC filings (Ticker: SNPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Synopsys funds relentless R&D, books multi-year license revenue, or discloses its latest IP acquisition can feel like decoding a 300-page textbook. That complexity is why questions such as “Synopsys SEC filings explained simply” or “Synopsys insider trading Form 4 transactions” appear so often in search boxes.
Stock Titan solves the puzzle. Our platform delivers AI-powered summaries that turn every Synopsys annual report 10-K simplified, each Synopsys quarterly earnings report 10-Q filing, and even the briefest Synopsys 8-K material events explained into clear narrative. Need real-time alerts? Synopsys Form 4 insider transactions real-time show exactly when executives exercise options, while the dashboard links directly to Synopsys executive stock transactions Form 4 for deeper context. You’ll also find side-by-side Synopsys proxy statement executive compensation tables and concise Synopsys earnings report filing analysis, all updated the moment EDGAR releases.
The result: faster insight into how EDA tools, semiconductor IP, and software-security services shape revenue streams; instant visibility on share repurchases or option grants; and confidence when comparing backlog trends quarter-over-quarter. Whether you’re monitoring dilution risk, studying segment margins, or simply understanding Synopsys SEC documents with AI, every filing type—10-K, 10-Q, 8-K, S-8, or Form 4—is ready when you are, explained in language that empowers decisive action.
Synopsys, Inc. (SNPS) filed an 8-K to disclose that the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) has rescinded the export restrictions that were imposed on certain Synopsys products sold into China on May 29, 2025. The rescission is effective immediately as of July 2, 2025.
The company states it is "working to restore access" for Chinese customers to the previously restricted products and is still evaluating how the temporary restrictions may affect its business, operating results, and overall financial condition. No quantitative impact or guidance revisions were provided in the filing. Management reminds investors that forward-looking statements are subject to risks and uncertainties disclosed in prior SEC reports.
While the 8-K contains no earnings data, the lifting of restrictions removes a potential headwind to Synopsys’ sales in a strategically important market. The filing does not mention any conditions, penalties, or ongoing limitations attached to the BIS decision. The company has not updated its outlook and expressly disclaims any obligation to do so after July 2, 2025.
Schedule 13G Overview: Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC (the “Reporting Persons”) disclosed a collective 9.99 % beneficial ownership in Processa Pharmaceuticals Inc. (PCSA) common stock as of 20 June 2025.
Current Position (3,018,238 shares):
- 2,430,000 shares held outright by Intracoastal
- 260,000 shares issuable on exercise of Intracoastal Warrant 1
- 328,238 shares issuable on exercise of Intracoastal Warrant 2
The stake is calculated against a reference total of 30,807, (11,884,356 pre-transaction shares plus shares issued/issuable in connection with the Securities Purchase Agreement (“SPA”) executed on 17 June 2025).
Warrant Structure & Blockers: Both Intracoastal warrants contain a 9.99 % ownership blocker that prevents exercises which would push the Reporting Persons’ combined holding above that threshold. Absent these blockers, the group could control up to 10,000,000 shares.
Securities Purchase Agreement Highlights: • 1,310,000 new shares issued to Intracoastal at closing • Two warrants (Warrant 1 & Warrant 2) issued concurrently. The SPA and subsequent warrant exercises are the primary drivers of the current 9.99 % position.
Regulatory Classification: Kopin and Asher are individuals (HC, IN), while Intracoastal is a Delaware LLC (OO). The filing is made under Rule 13d-1(c).
Form 4 snapshot: Jaguar Health, Inc. (JAGX) director John Micek reported a series of related transactions dated 06/24/2025 that modify his derivative exposure to company equity.
Key transactions
- Exchange of 6% Convertible Note: Micek disposed of the original 6% note maturing 06/30/2025 that was convertible into 9,000 common shares. In its place he acquired a new 6% promissory note maturing 01/30/2026, convertible at the holder’s option into 9,462 common shares at a conversion price of $5.555 per share.
- Inducement warrant: As consideration for the exchange, he received a warrant to purchase up to 18,262 common shares at an exercise price of $2.70. The warrant becomes exercisable once shareholder approval is obtained and will lapse on the earliest of (i) 18 months after issuance, (ii) the completion of a fundamental transaction, or (iii) a liquidation event.
Post-transaction holdings (derivatives only)
- Convertible Note (new): 9,462 underlying shares
- Warrant: 9,000 derivative securities beneficially owned (table value) with an aggregate right to purchase 18,262 shares
Implications for investors
- The new note extends the debt maturity by seven months, modestly improving Jaguar’s near-term cash-flow pressure.
- The combined instruments create potential dilution of up to 27,724 additional shares (9,462 from conversion + 18,262 from warrant) once fully exercised/converted.
- The warrant strike price ($2.70) is significantly below the note conversion price ($5.555), suggesting a higher likelihood of exercise if market price exceeds $2.70 post-approval.
FAQ
What is the current stock price of Synopsys (SNPS)?
What is the market cap of Synopsys (SNPS)?
What is the core business of Synopsys Inc?
How does Synopsys support semiconductor and systems companies?
What industries benefit from Synopsys' solutions?
How does Synopsys generate revenue?
What competitive advantages does Synopsys offer?
How is Synopsys positioned in the market?
Can you explain the significance of software quality and security in Synopsys' offerings?
How does Synopsys address the challenges of modern chip design?
